It Only Takes One Biotech Bull Market To Make You Rich... And It’s Here Now

This Is Your Opportunity To Make Massive Gains As An Investor

This is Porter’s Daily Journal, a free e-letter from Porter & Co. that provides unfiltered insights on markets, the economy, and life to help readers become better investors. It includes weekday editions and two weekend editions… and is free to all subscribers.

Table of Contents

• This Is Your Opportunity To Make Massive Gains As …

• Here’s What You Need To Know

• Three Things To Know Before We Go…

• And One More Thing… History Repeats For Kinsale

• Poll Results

About 18 months ago, I gave you an extraordinary piece of advice.

I pointed out that since the lows of 2022, while tech stocks (like semiconductors) had rallied – the iShares Semiconductor ETF (SOXX) was up 67% in 2022 – biotech stocks were mired in the worst bear market the sector had ever seen. From February 2021 to early 2022, the main biotech ETF, SPDR S&P Biotech (XBI), fell 50%, marking the worst drawdown in its history. And by January of 2024, there were hundreds of small-cap biotech stocks trading for less than the value of the cash on their balance sheets.

I’d never seen a more valuable dichotomy in my career. And, in my typical fashion, I explained how this set-up was the easiest way to make huge returns: horse, meet water.

What was the response from my dear paid-up subscribers? Crickets.

While Biotech Frontiers, the biotech newsletter we launched with investment legend Erez Kalir, racked up huge win after huge win, we couldn’t give it away. Fewer than 50 people subscribed. A once-in-a-lifetime booming biotech rally was inevitable. We were going to put up ridiculous returns. No one cared.

Since then, as I knew he would, Erez has compiled our firm’s best track record with an average annualized return of 54.5%. 

Here are some of his biggest winners…